Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Outlook Therapeutics (OTLK) Other Non Operating Income (2017 - 2020)

Historic Other Non Operating Income for Outlook Therapeutics (OTLK) over the last 3 years, with Q2 2020 value amounting to $6.2 million.

  • Outlook Therapeutics' Other Non Operating Income rose 155491.8% to $6.2 million in Q2 2020 from the same period last year, while for Jun 2020 it was -$1.9 million, marking a year-over-year decrease of 21228.11%. This contributed to the annual value of -$577659.0 for FY2023, which is 4366.51% up from last year.
  • According to the latest figures from Q2 2020, Outlook Therapeutics' Other Non Operating Income is $6.2 million, which was up 155491.8% from -$8.1 million recorded in Q4 2019.
  • In the past 5 years, Outlook Therapeutics' Other Non Operating Income ranged from a high of $6.2 million in Q2 2020 and a low of -$8.1 million during Q4 2019
  • In the last 3 years, Outlook Therapeutics' Other Non Operating Income had a median value of -$423686.0 in 2019 and averaged -$751177.8.
  • Data for Outlook Therapeutics' Other Non Operating Income shows a peak YoY increase of 155491.8% (in 2020) and a maximum YoY decrease of 155491.8% (in 2020) over the last 5 years.
  • Quarter analysis of 3 years shows Outlook Therapeutics' Other Non Operating Income stood at -$1.3 million in 2017, then plummeted by 543.63% to -$8.1 million in 2019, then soared by 176.47% to $6.2 million in 2020.
  • Its Other Non Operating Income was $6.2 million in Q2 2020, compared to -$8.1 million in Q4 2019 and -$423686.0 in Q2 2019.